glp-1 digital health platform startups Virtual startups: Pill mills or the future of obesity care? GLP-1 Market Trends and Global

Q., Ren, C., Xia, Z

In a phase 2 trial, people with T2D and overweight/obesity achieved greater mean WL with cagrisema 2.4 mg compared to cagrilintide 2.4 mg or semaglutide 2.4 mg alone after 32 weeks of treatment (15.6% WL vs

Kennedy Jr., who has said hes a big fan. Essentially smaller versions of proteins, peptides are being touted for everything from skin rejuvenation and hair growth to gut health and injury recovery despite a lack of scientific evidence to back up these claims

Recent Developments: As of mid-2026, the FDA has proposed to exclude popular GLP-1 substances like Semaglutide, Tirzepatide, and Liraglutide from the list, concluding that there is no clinical need to compound them from bulk ingredients when approved versions are available

Try Our Customized Service

Research identifies over 4,000 genes influenced by this compound, affecting everything from collagen production to inflammation to wound healing